Cargando…

Effectiveness of a Female Community Health Volunteer–Delivered Intervention in Reducing Blood Glucose Among Adults With Type 2 Diabetes: An Open-Label, Cluster Randomized Clinical Trial

IMPORTANCE: Female community health volunteers (FCHVs) are frontline community health workers who have been a valuable resource in improving public health outcomes in Nepal, but their value is understudied in diabetes care. OBJECTIVE: To assess whether an FCHV-delivered intervention is associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyawali, Bishal, Sharma, Rajan, Mishra, Shiva Raj, Neupane, Dinesh, Vaidya, Abhinav, Sandbæk, Annelli, Kallestrup, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851734/
https://www.ncbi.nlm.nih.gov/pubmed/33523189
http://dx.doi.org/10.1001/jamanetworkopen.2020.35799
_version_ 1783645683020988416
author Gyawali, Bishal
Sharma, Rajan
Mishra, Shiva Raj
Neupane, Dinesh
Vaidya, Abhinav
Sandbæk, Annelli
Kallestrup, Per
author_facet Gyawali, Bishal
Sharma, Rajan
Mishra, Shiva Raj
Neupane, Dinesh
Vaidya, Abhinav
Sandbæk, Annelli
Kallestrup, Per
author_sort Gyawali, Bishal
collection PubMed
description IMPORTANCE: Female community health volunteers (FCHVs) are frontline community health workers who have been a valuable resource in improving public health outcomes in Nepal, but their value is understudied in diabetes care. OBJECTIVE: To assess whether an FCHV-delivered intervention is associated with reduced blood glucose levels among adults with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: This community-based, open-label, 2-group, cluster randomized clinical trial with a 12-month delayed control group design was conducted in 14 clusters of a semiurban setting in Western Nepal. A total of 244 adults with type 2 diabetes were recruited between November 2016 and April 2017. The follow-up assessment was conducted at 12 months after enrollment. Data analysis was performed from January to February 2019. INTERVENTIONS: Seven clusters were randomized to the FCHV-delivered intervention in which 20 FCHVs provided home visits 3 times a year (once every 4 months) for health promotion counseling and blood glucose monitoring. If participants had blood glucose levels of 126 mg/dL or higher, the FCHVs referred them to the nearest health facility, and if participants were taking antihyperglycemic medication, they were followed up by the FCHVs for adherence to their medication. Seven clusters were randomized to usual care (control group). MAIN OUTCOMES AND MEASURES: The primary outcome was the change in mean fasting blood glucose from baseline to 12-month follow-up. Secondary outcomes included changes in mean systolic blood pressure, mean diastolic blood pressure, mean body mass index, percentage change in the proportion of low physical activity, harmful alcohol consumption, current smoking, low fruit and vegetable intake, and antihyperglycemic medication status. RESULTS: Of 244 participants, 120 women (56.6%) and 92 men (43.4%) completed the trial. At baseline, the mean (SD) age was 51.71 (8.77) years; 127 participants were in the intervention group, and 117 participants were in the control group (usual care). At baseline, the mean (SD) fasting blood glucose level was 156.06 (44.48) mg/dL (158.48 [45.50] mg/dL in the intervention group and 153.43 [43.39] mg/dL in the control group). At 12-month follow-up, the mean fasting blood glucose decreased by 22.86 mg/dL in the intervention group, whereas it increased by 7.38 mg/dL in the control group. The mean reduction was 27.90 mg/dL greater with the intervention (95% CI, −37.62 to −18.18 mg/dL; P < .001). In secondary outcome analyses, there was a greater decline in mean systolic blood pressure in the intervention group than in the control group (−5.40 mm Hg; 95% CI, −8.88 to −1.92 mm Hg; P = .002). There was detectable difference in the intake of antihyperglycemic medication between the groups (relative risk, 1.35; 95% CI, 1.1 to 1.74; P = .02). CONCLUSIONS AND RELEVANCE: These findings suggest that an FCHV-delivered intervention is associated with reduced blood glucose levels among adults with type 2 diabetes in a low-resource setting in Nepal. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03304158
format Online
Article
Text
id pubmed-7851734
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-78517342021-02-11 Effectiveness of a Female Community Health Volunteer–Delivered Intervention in Reducing Blood Glucose Among Adults With Type 2 Diabetes: An Open-Label, Cluster Randomized Clinical Trial Gyawali, Bishal Sharma, Rajan Mishra, Shiva Raj Neupane, Dinesh Vaidya, Abhinav Sandbæk, Annelli Kallestrup, Per JAMA Netw Open Original Investigation IMPORTANCE: Female community health volunteers (FCHVs) are frontline community health workers who have been a valuable resource in improving public health outcomes in Nepal, but their value is understudied in diabetes care. OBJECTIVE: To assess whether an FCHV-delivered intervention is associated with reduced blood glucose levels among adults with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: This community-based, open-label, 2-group, cluster randomized clinical trial with a 12-month delayed control group design was conducted in 14 clusters of a semiurban setting in Western Nepal. A total of 244 adults with type 2 diabetes were recruited between November 2016 and April 2017. The follow-up assessment was conducted at 12 months after enrollment. Data analysis was performed from January to February 2019. INTERVENTIONS: Seven clusters were randomized to the FCHV-delivered intervention in which 20 FCHVs provided home visits 3 times a year (once every 4 months) for health promotion counseling and blood glucose monitoring. If participants had blood glucose levels of 126 mg/dL or higher, the FCHVs referred them to the nearest health facility, and if participants were taking antihyperglycemic medication, they were followed up by the FCHVs for adherence to their medication. Seven clusters were randomized to usual care (control group). MAIN OUTCOMES AND MEASURES: The primary outcome was the change in mean fasting blood glucose from baseline to 12-month follow-up. Secondary outcomes included changes in mean systolic blood pressure, mean diastolic blood pressure, mean body mass index, percentage change in the proportion of low physical activity, harmful alcohol consumption, current smoking, low fruit and vegetable intake, and antihyperglycemic medication status. RESULTS: Of 244 participants, 120 women (56.6%) and 92 men (43.4%) completed the trial. At baseline, the mean (SD) age was 51.71 (8.77) years; 127 participants were in the intervention group, and 117 participants were in the control group (usual care). At baseline, the mean (SD) fasting blood glucose level was 156.06 (44.48) mg/dL (158.48 [45.50] mg/dL in the intervention group and 153.43 [43.39] mg/dL in the control group). At 12-month follow-up, the mean fasting blood glucose decreased by 22.86 mg/dL in the intervention group, whereas it increased by 7.38 mg/dL in the control group. The mean reduction was 27.90 mg/dL greater with the intervention (95% CI, −37.62 to −18.18 mg/dL; P < .001). In secondary outcome analyses, there was a greater decline in mean systolic blood pressure in the intervention group than in the control group (−5.40 mm Hg; 95% CI, −8.88 to −1.92 mm Hg; P = .002). There was detectable difference in the intake of antihyperglycemic medication between the groups (relative risk, 1.35; 95% CI, 1.1 to 1.74; P = .02). CONCLUSIONS AND RELEVANCE: These findings suggest that an FCHV-delivered intervention is associated with reduced blood glucose levels among adults with type 2 diabetes in a low-resource setting in Nepal. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03304158 American Medical Association 2021-02-01 /pmc/articles/PMC7851734/ /pubmed/33523189 http://dx.doi.org/10.1001/jamanetworkopen.2020.35799 Text en Copyright 2021 Gyawali B et al. JAMA Network Open. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Gyawali, Bishal
Sharma, Rajan
Mishra, Shiva Raj
Neupane, Dinesh
Vaidya, Abhinav
Sandbæk, Annelli
Kallestrup, Per
Effectiveness of a Female Community Health Volunteer–Delivered Intervention in Reducing Blood Glucose Among Adults With Type 2 Diabetes: An Open-Label, Cluster Randomized Clinical Trial
title Effectiveness of a Female Community Health Volunteer–Delivered Intervention in Reducing Blood Glucose Among Adults With Type 2 Diabetes: An Open-Label, Cluster Randomized Clinical Trial
title_full Effectiveness of a Female Community Health Volunteer–Delivered Intervention in Reducing Blood Glucose Among Adults With Type 2 Diabetes: An Open-Label, Cluster Randomized Clinical Trial
title_fullStr Effectiveness of a Female Community Health Volunteer–Delivered Intervention in Reducing Blood Glucose Among Adults With Type 2 Diabetes: An Open-Label, Cluster Randomized Clinical Trial
title_full_unstemmed Effectiveness of a Female Community Health Volunteer–Delivered Intervention in Reducing Blood Glucose Among Adults With Type 2 Diabetes: An Open-Label, Cluster Randomized Clinical Trial
title_short Effectiveness of a Female Community Health Volunteer–Delivered Intervention in Reducing Blood Glucose Among Adults With Type 2 Diabetes: An Open-Label, Cluster Randomized Clinical Trial
title_sort effectiveness of a female community health volunteer–delivered intervention in reducing blood glucose among adults with type 2 diabetes: an open-label, cluster randomized clinical trial
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851734/
https://www.ncbi.nlm.nih.gov/pubmed/33523189
http://dx.doi.org/10.1001/jamanetworkopen.2020.35799
work_keys_str_mv AT gyawalibishal effectivenessofafemalecommunityhealthvolunteerdeliveredinterventioninreducingbloodglucoseamongadultswithtype2diabetesanopenlabelclusterrandomizedclinicaltrial
AT sharmarajan effectivenessofafemalecommunityhealthvolunteerdeliveredinterventioninreducingbloodglucoseamongadultswithtype2diabetesanopenlabelclusterrandomizedclinicaltrial
AT mishrashivaraj effectivenessofafemalecommunityhealthvolunteerdeliveredinterventioninreducingbloodglucoseamongadultswithtype2diabetesanopenlabelclusterrandomizedclinicaltrial
AT neupanedinesh effectivenessofafemalecommunityhealthvolunteerdeliveredinterventioninreducingbloodglucoseamongadultswithtype2diabetesanopenlabelclusterrandomizedclinicaltrial
AT vaidyaabhinav effectivenessofafemalecommunityhealthvolunteerdeliveredinterventioninreducingbloodglucoseamongadultswithtype2diabetesanopenlabelclusterrandomizedclinicaltrial
AT sandbækannelli effectivenessofafemalecommunityhealthvolunteerdeliveredinterventioninreducingbloodglucoseamongadultswithtype2diabetesanopenlabelclusterrandomizedclinicaltrial
AT kallestrupper effectivenessofafemalecommunityhealthvolunteerdeliveredinterventioninreducingbloodglucoseamongadultswithtype2diabetesanopenlabelclusterrandomizedclinicaltrial